The global GLP-1/GIP Dual Receptor Agonist market was valued at US$ 33116 million in 2025 and is anticipated to reach US$ 69261 million by 2032, at a CAGR of 11.0% from 2026 to 2032.

GLP-1/GIP Dual Receptor Agonist Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on GLP-1/GIP Dual Receptor Agonist competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

In 2025, global GLP-1/GIP Dual Receptor Agonist production reached approximately 188.95 M Units, with an average global market price of around 175.26 USD per Unit.

A GLP-1/GIP dual receptor agonist is a single therapeutic agent (usually a peptide) designed to activate both the GLP-1 receptor (GLP-1R) and the GIP receptor (GIPR). By stimulating these two incretin pathways together, it aims to improve metabolic control—typically by enhancing glucose-dependent insulin secretion, reducing glucagon when appropriate, slowing gastric emptying, and decreasing appetite/food intake—so it can support blood-glucose lowering and weight loss in conditions such as type 2 diabetes and obesity.To date, Tirzepatide is the only commercially available GLP-1/GIP dual receptor agonist product in the world.

GLP-1/GIP dual receptor agonists are reshaping the incretin field because they tackle a long-standing clinical and commercial pain point in metabolic care: achieving meaningful, sustained weight reduction and cardiometabolic improvement without forcing patients and providers into a tradeoff between efficacy, tolerability, and long-term adherence. By co-activating GLP-1 and GIP pathways in a single molecule, these therapies can deliver a broader metabolic effect than GLP-1 alone—supporting glucose control while driving appetite reduction and weight loss that can translate into improvements across obesity-linked comorbidities—while modern long-acting designs and carefully tuned receptor balance aim to preserve potency with manageable gastrointestinal burden and simpler dosing routines. Industry momentum is being driven by unprecedented demand for effective obesity and diabetes treatments, rising recognition of obesity as a chronic disease with downstream health-system costs, strong payer and employer interest in outcomes that reduce long-term risk, and rapid advances in peptide engineering, formulation, and device delivery that make scalable, patient-friendly products feasible. The market potential remains substantial as dual agonists expand from specialist-driven use toward broader chronic-care adoption, diversify into new formulations and delivery formats, and compete through differentiation on tolerability, durability of effect, and real-world outcomes, positioning the category as a durable growth engine within biopharma’s most strategically important therapeutic area.

The upstream raw materials for GLP-1/GIP Dual Receptor Agonist mainly include amino acids, condensation reagents, activators, resin carriers, etc. Typical raw material suppliers include Merck, Bachem, AAPPTec, Thermo Fisher, etc. The downstream applications are mainly in the treatment of obesity and diabetes.

The single-line production capacity of GLP-1/GIP dual receptor agonist varies significantly depending on the drug molecule type, process complexity, equipment scale, and production mode. Industry gross margins typically range from 60% to 80%.

The North American market for GLP-1/GIP Dual Receptor Agonist is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for GLP-1/GIP Dual Receptor Agonist is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of GLP-1/GIP Dual Receptor Agonist include Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global GLP-1/GIP Dual Receptor Agonist market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding GLP-1/GIP Dual Receptor Agonist. The GLP-1/GIP Dual Receptor Agonist market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global GLP-1/GIP Dual Receptor Agonist market comprehensively. Regional market sizes by Type, by Application, by Receptor Agonist Properties, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist GLP-1/GIP Dual Receptor Agonist manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of GLP-1/GIP Dual Receptor Agonist Market Report

Report Metric	Details
Report Name	GLP-1/GIP Dual Receptor Agonist Market
Accounted market size in 2025	US$ 33116 in million
Forecasted market size in 2032	US$ 69261 million
CAGR	11.0%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Balanced Biased Others
Segment by Receptor Agonist Properties	Balanced Biased Others
Segment by Medicinal Efficacy	Long-acting Short-acting
by Application	Diabetes Obesity Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, by Receptor Agonist Properties, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for GLP-1/GIP Dual Receptor Agonist manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines GLP-1/GIP Dual Receptor Agonist sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is GLP-1/GIP Dual Receptor Agonist Market growing?

Ans: The GLP-1/GIP Dual Receptor Agonist Market witnessing a CAGR of 11.0% during the forecast period 2026-2032.

What is the GLP-1/GIP Dual Receptor Agonist Market size in 2032?

Ans: The GLP-1/GIP Dual Receptor Agonist Market size in 2032 will be US$ 69261 million.

Who are the main players in the GLP-1/GIP Dual Receptor Agonist Market report?

Ans: The main players in the GLP-1/GIP Dual Receptor Agonist Market are Eli Lilly, Roche, Viking Therapeutics, Ascletis Pharma, Jiangsu Hengrui Medicine, East China Pharmaceutical, Tonghua Dongbao Pharmaceutical, Lepu Medical Technology, Hansoh Pharma

What are the Application segmentation covered in the GLP-1/GIP Dual Receptor Agonist Market report?

Ans: The Applications covered in the GLP-1/GIP Dual Receptor Agonist Market report are Diabetes, Obesity, Others

What are the Type segmentation covered in the GLP-1/GIP Dual Receptor Agonist Market report?

Ans: The Types covered in the GLP-1/GIP Dual Receptor Agonist Market report are Balanced, Biased, Others

1 GLP-1/GIP Dual Receptor Agonist Market Overview

1.1 Product Definition

1.2 GLP-1/GIP Dual Receptor Agonist by Type

1.2.1 Global GLP-1/GIP Dual Receptor Agonist Market Value by Type: 2025 vs 2032

1.2.2 Balanced

1.2.3 Biased

1.2.4 Others

1.3 GLP-1/GIP Dual Receptor Agonist by Receptor Agonist Properties

1.3.1 Global GLP-1/GIP Dual Receptor Agonist Market Value by Receptor Agonist Properties: 2025 vs 2032

1.3.2 Balanced

1.3.3 Biased

1.3.4 Others

1.4 GLP-1/GIP Dual Receptor Agonist by Medicinal Efficacy

1.4.1 Global GLP-1/GIP Dual Receptor Agonist Market Value by Medicinal Efficacy: 2025 vs 2032

1.4.2 Long-acting

1.4.3 Short-acting

1.5 GLP-1/GIP Dual Receptor Agonist by Application

1.5.1 Global GLP-1/GIP Dual Receptor Agonist Market Value by Application: 2025 vs 2032

1.5.2 Diabetes

1.5.3 Obesity

1.5.4 Others

1.6 Global GLP-1/GIP Dual Receptor Agonist Market Size Estimates and Forecasts

1.6.1 Global GLP-1/GIP Dual Receptor Agonist Revenue 2021–2032

1.6.2 Global GLP-1/GIP Dual Receptor Agonist Sales 2021–2032

1.6.3 Global GLP-1/GIP Dual Receptor Agonist Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2 GLP-1/GIP Dual Receptor Agonist Market Competition by Manufacturers

2.1 Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Manufacturers (2021–2026)

2.2 Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Manufacturers (2021–2026)

2.3 Global GLP-1/GIP Dual Receptor Agonist Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of GLP-1/GIP Dual Receptor Agonist, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Product Types and Applications

2.7 Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Date of Entry into the Industry

2.8 Global GLP-1/GIP Dual Receptor Agonist Market Competitive Situation and Trends

2.8.1 Global GLP-1/GIP Dual Receptor Agonist Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global GLP-1/GIP Dual Receptor Agonist Players Market Share by Revenue

2.8.3 Global GLP-1/GIP Dual Receptor Agonist Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global GLP-1/GIP Dual Receptor Agonist Market Scenario by Region

3.1 Global GLP-1/GIP Dual Receptor Agonist Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global GLP-1/GIP Dual Receptor Agonist Sales by Region: 2021–2032

3.2.1 Global GLP-1/GIP Dual Receptor Agonist Sales by Region: 2021–2026

3.2.2 Global GLP-1/GIP Dual Receptor Agonist Sales by Region: 2027–2032

3.3 Global GLP-1/GIP Dual Receptor Agonist Revenue by Region: 2021–2032

3.3.1 Global GLP-1/GIP Dual Receptor Agonist Revenue by Region: 2021–2026

3.3.2 Global GLP-1/GIP Dual Receptor Agonist Revenue by Region: 2027–2032

3.4 North America GLP-1/GIP Dual Receptor Agonist Market Facts & Figures by Country

3.4.1 North America GLP-1/GIP Dual Receptor Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America GLP-1/GIP Dual Receptor Agonist Sales by Country (2021–2032)

3.4.3 North America GLP-1/GIP Dual Receptor Agonist Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe GLP-1/GIP Dual Receptor Agonist Market Facts & Figures by Country

3.5.1 Europe GLP-1/GIP Dual Receptor Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe GLP-1/GIP Dual Receptor Agonist Sales by Country (2021–2032)

3.5.3 Europe GLP-1/GIP Dual Receptor Agonist Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific GLP-1/GIP Dual Receptor Agonist Market Facts & Figures by Region

3.6.1 Asia Pacific GLP-1/GIP Dual Receptor Agonist Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific GLP-1/GIP Dual Receptor Agonist Sales by Region (2021–2032)

3.6.3 Asia Pacific GLP-1/GIP Dual Receptor Agonist Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America GLP-1/GIP Dual Receptor Agonist Market Facts & Figures by Country

3.7.1 Latin America GLP-1/GIP Dual Receptor Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America GLP-1/GIP Dual Receptor Agonist Sales by Country (2021–2032)

3.7.3 Latin America GLP-1/GIP Dual Receptor Agonist Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa GLP-1/GIP Dual Receptor Agonist Market Facts & Figures by Country

3.8.1 Middle East and Africa GLP-1/GIP Dual Receptor Agonist Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa GLP-1/GIP Dual Receptor Agonist Sales by Country (2021–2032)

3.8.3 Middle East and Africa GLP-1/GIP Dual Receptor Agonist Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global GLP-1/GIP Dual Receptor Agonist Sales by Type (2021–2032)

4.1.1 Global GLP-1/GIP Dual Receptor Agonist Sales by Type (2021–2026)

4.1.2 Global GLP-1/GIP Dual Receptor Agonist Sales by Type (2027–2032)

4.1.3 Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Type (2021–2032)

4.2 Global GLP-1/GIP Dual Receptor Agonist Revenue by Type (2021–2032)

4.2.1 Global GLP-1/GIP Dual Receptor Agonist Revenue by Type (2021–2026)

4.2.2 Global GLP-1/GIP Dual Receptor Agonist Revenue by Type (2027–2032)

4.2.3 Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Type (2021–2032)

4.3 Global GLP-1/GIP Dual Receptor Agonist Price by Type (2021–2032)

5 Segment by Application

5.1 Global GLP-1/GIP Dual Receptor Agonist Sales by Application (2021–2032)

5.1.1 Global GLP-1/GIP Dual Receptor Agonist Sales by Application (2021–2026)

5.1.2 Global GLP-1/GIP Dual Receptor Agonist Sales by Application (2027–2032)

5.1.3 Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Application (2021–2032)

5.2 Global GLP-1/GIP Dual Receptor Agonist Revenue by Application (2021–2032)

5.2.1 Global GLP-1/GIP Dual Receptor Agonist Revenue by Application (2021–2026)

5.2.2 Global GLP-1/GIP Dual Receptor Agonist Revenue by Application (2027–2032)

5.2.3 Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Application (2021–2032)

5.3 Global GLP-1/GIP Dual Receptor Agonist Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Eli Lilly

6.1.1 Eli Lilly Company Information

6.1.2 Eli Lilly Description and Business Overview

6.1.3 Eli Lilly GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Eli Lilly GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.1.5 Eli Lilly Recent Developments/Updates

6.2 Roche

6.2.1 Roche Company Information

6.2.2 Roche Description and Business Overview

6.2.3 Roche GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Roche GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.2.5 Roche Recent Developments/Updates

6.3 Viking Therapeutics

6.3.1 Viking Therapeutics Company Information

6.3.2 Viking Therapeutics Description and Business Overview

6.3.3 Viking Therapeutics GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Viking Therapeutics GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.3.5 Viking Therapeutics Recent Developments/Updates

6.4 Ascletis Pharma

6.4.1 Ascletis Pharma Company Information

6.4.2 Ascletis Pharma Description and Business Overview

6.4.3 Ascletis Pharma GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 Ascletis Pharma GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.4.5 Ascletis Pharma Recent Developments/Updates

6.5 Jiangsu Hengrui Medicine

6.5.1 Jiangsu Hengrui Medicine Company Information

6.5.2 Jiangsu Hengrui Medicine Description and Business Overview

6.5.3 Jiangsu Hengrui Medicine GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 Jiangsu Hengrui Medicine GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.5.5 Jiangsu Hengrui Medicine Recent Developments/Updates

6.6 East China Pharmaceutical

6.6.1 East China Pharmaceutical Company Information

6.6.2 East China Pharmaceutical Description and Business Overview

6.6.3 East China Pharmaceutical GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 East China Pharmaceutical GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.6.5 East China Pharmaceutical Recent Developments/Updates

6.7 Tonghua Dongbao Pharmaceutical

6.7.1 Tonghua Dongbao Pharmaceutical Company Information

6.7.2 Tonghua Dongbao Pharmaceutical Description and Business Overview

6.7.3 Tonghua Dongbao Pharmaceutical GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.7.4 Tonghua Dongbao Pharmaceutical GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.7.5 Tonghua Dongbao Pharmaceutical Recent Developments/Updates

6.8 Lepu Medical Technology

6.8.1 Lepu Medical Technology Company Information

6.8.2 Lepu Medical Technology Description and Business Overview

6.8.3 Lepu Medical Technology GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.8.4 Lepu Medical Technology GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.8.5 Lepu Medical Technology Recent Developments/Updates

6.9 Hansoh Pharma

6.9.1 Hansoh Pharma Company Information

6.9.2 Hansoh Pharma Description and Business Overview

6.9.3 Hansoh Pharma GLP-1/GIP Dual Receptor Agonist Sales, Revenue, and Gross Margin (2021–2026)

6.9.4 Hansoh Pharma GLP-1/GIP Dual Receptor Agonist Product Portfolio

6.9.5 Hansoh Pharma Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 GLP-1/GIP Dual Receptor Agonist Industry Chain Analysis

7.2 GLP-1/GIP Dual Receptor Agonist Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 GLP-1/GIP Dual Receptor Agonist Production Mode & Process Analysis

7.4 GLP-1/GIP Dual Receptor Agonist Sales and Marketing

7.4.1 GLP-1/GIP Dual Receptor Agonist Sales Channels

7.4.2 GLP-1/GIP Dual Receptor Agonist Distributors

7.5 GLP-1/GIP Dual Receptor Agonist Customer Analysis

8 GLP-1/GIP Dual Receptor Agonist Market Dynamics

8.1 GLP-1/GIP Dual Receptor Agonist Industry Trends

8.2 GLP-1/GIP Dual Receptor Agonist Market Drivers

8.3 GLP-1/GIP Dual Receptor Agonist Market Challenges

8.4 GLP-1/GIP Dual Receptor Agonist Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Jiangsu Hengrui Medicine

East China Pharmaceutical

Tonghua Dongbao Pharmaceutical

Lepu Medical Technology

Hansoh Pharma

List of Tables

Table 1. Global GLP-1/GIP Dual Receptor Agonist Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global GLP-1/GIP Dual Receptor Agonist Market Value by Receptor Agonist Properties (US$ Million), 2025 vs 2032

Table 3. Global GLP-1/GIP Dual Receptor Agonist Market Value by Medicinal Efficacy (US$ Million), 2025 vs 2032

Table 4. Global GLP-1/GIP Dual Receptor Agonist Market Value by Application (US$ Million), 2025 vs 2032

Table 5. Global GLP-1/GIP Dual Receptor Agonist Market Competitive Situation by Manufacturers in 2025

Table 6. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units) of Key Manufacturers (2021–2026)

Table 7. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Manufacturers (2021–2026)

Table 8. Global GLP-1/GIP Dual Receptor Agonist Revenue (US$ Million) by Manufacturers (2021–2026)

Table 9. Global GLP-1/GIP Dual Receptor Agonist Revenue Share by Manufacturers (2021–2026)

Table 10. Global Market GLP-1/GIP Dual Receptor Agonist Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 11. Global Key Players of GLP-1/GIP Dual Receptor Agonist, Industry Ranking, 2023 vs 2024 vs 2025

Table 12. Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Manufacturing Sites and Headquarters

Table 13. Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Product Types and Applications

Table 14. Global Key Manufacturers of GLP-1/GIP Dual Receptor Agonist, Date of Entry into the Industry

Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 16. Global GLP-1/GIP Dual Receptor Agonist Companies by Tier (Tier 1, Tier 2, Tier 3), based on GLP-1/GIP Dual Receptor Agonist Revenue, 2025

Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 18. Global GLP-1/GIP Dual Receptor Agonist Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 19. Global GLP-1/GIP Dual Receptor Agonist Sales by Region (K Units), 2021–2026

Table 20. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Region (2021–2026)

Table 21. Global GLP-1/GIP Dual Receptor Agonist Sales by Region (K Units), 2027–2032

Table 22. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Region (2027–2032)

Table 23. Global GLP-1/GIP Dual Receptor Agonist Revenue by Region (US$ Million), 2021–2026

Table 24. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Region (2021–2026)

Table 25. Global GLP-1/GIP Dual Receptor Agonist Revenue by Region (US$ Million), 2027–2032

Table 26. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Region (2027–2032)

Table 27. North America GLP-1/GIP Dual Receptor Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 28. North America GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2021–2026

Table 29. North America GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2027–2032

Table 30. North America GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2021–2026

Table 31. North America GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2027–2032

Table 32. Europe GLP-1/GIP Dual Receptor Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 33. Europe GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2021–2026

Table 34. Europe GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2027–2032

Table 35. Europe GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2021–2026

Table 36. Europe GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2027–2032

Table 37. Asia Pacific GLP-1/GIP Dual Receptor Agonist Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 38. Asia Pacific GLP-1/GIP Dual Receptor Agonist Sales by Region (K Units), 2021–2026

Table 39. Asia Pacific GLP-1/GIP Dual Receptor Agonist Sales by Region (K Units), 2027–2032

Table 40. Asia Pacific GLP-1/GIP Dual Receptor Agonist Revenue by Region (US$ Million), 2021–2026

Table 41. Asia Pacific GLP-1/GIP Dual Receptor Agonist Revenue by Region (US$ Million), 2027–2032

Table 42. Latin America GLP-1/GIP Dual Receptor Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 43. Latin America GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2021–2026

Table 44. Latin America GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2027–2032

Table 45. Latin America GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2021–2026

Table 46. Latin America GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2027–2032

Table 47. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 48. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2021–2026

Table 49. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Sales by Country (K Units), 2027–2032

Table 50. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2021–2026

Table 51. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Revenue by Country (US$ Million), 2027–2032

Table 52. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units) by Type (2021–2026)

Table 53. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units) by Type (2027–2032)

Table 54. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Type (2021–2026)

Table 55. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Type (2027–2032)

Table 56. Global GLP-1/GIP Dual Receptor Agonist Revenue (US$ Million) by Type (2021–2026)

Table 57. Global GLP-1/GIP Dual Receptor Agonist Revenue (US$ Million) by Type (2027–2032)

Table 58. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Type (2021–2026)

Table 59. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Type (2027–2032)

Table 60. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Type (2021–2026)

Table 61. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Type (2027–2032)

Table 62. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units) by Application (2021–2026)

Table 63. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units) by Application (2027–2032)

Table 64. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Application (2021–2026)

Table 65. Global GLP-1/GIP Dual Receptor Agonist Sales Market Share by Application (2027–2032)

Table 66. Global GLP-1/GIP Dual Receptor Agonist Revenue (US$ Million) by Application (2021–2026)

Table 67. Global GLP-1/GIP Dual Receptor Agonist Revenue (US$ Million) by Application (2027–2032)

Table 68. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Application (2021–2026)

Table 69. Global GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Application (2027–2032)

Table 70. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Application (2021–2026)

Table 71. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Application (2027–2032)

Table 72. Eli Lilly Company Information

Table 73. Eli Lilly Description and Business Overview

Table 74. Eli Lilly GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 75. Eli Lilly GLP-1/GIP Dual Receptor Agonist Product

Table 76. Eli Lilly Recent Developments/Updates

Table 77. Roche Company Information

Table 78. Roche Description and Business Overview

Table 79. Roche GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 80. Roche GLP-1/GIP Dual Receptor Agonist Product

Table 81. Roche Recent Developments/Updates

Table 82. Viking Therapeutics Company Information

Table 83. Viking Therapeutics Description and Business Overview

Table 84. Viking Therapeutics GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 85. Viking Therapeutics GLP-1/GIP Dual Receptor Agonist Product

Table 86. Viking Therapeutics Recent Developments/Updates

Table 87. Ascletis Pharma Company Information

Table 88. Ascletis Pharma Description and Business Overview

Table 89. Ascletis Pharma GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 90. Ascletis Pharma GLP-1/GIP Dual Receptor Agonist Product

Table 91. Ascletis Pharma Recent Developments/Updates

Table 92. Jiangsu Hengrui Medicine Company Information

Table 93. Jiangsu Hengrui Medicine Description and Business Overview

Table 94. Jiangsu Hengrui Medicine GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 95. Jiangsu Hengrui Medicine GLP-1/GIP Dual Receptor Agonist Product

Table 96. Jiangsu Hengrui Medicine Recent Developments/Updates

Table 97. East China Pharmaceutical Company Information

Table 98. East China Pharmaceutical Description and Business Overview

Table 99. East China Pharmaceutical GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 100. East China Pharmaceutical GLP-1/GIP Dual Receptor Agonist Product

Table 101. East China Pharmaceutical Recent Developments/Updates

Table 102. Tonghua Dongbao Pharmaceutical Company Information

Table 103. Tonghua Dongbao Pharmaceutical Description and Business Overview

Table 104. Tonghua Dongbao Pharmaceutical GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 105. Tonghua Dongbao Pharmaceutical GLP-1/GIP Dual Receptor Agonist Product

Table 106. Tonghua Dongbao Pharmaceutical Recent Developments/Updates

Table 107. Lepu Medical Technology Company Information

Table 108. Lepu Medical Technology Description and Business Overview

Table 109. Lepu Medical Technology GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 110. Lepu Medical Technology GLP-1/GIP Dual Receptor Agonist Product

Table 111. Lepu Medical Technology Recent Developments/Updates

Table 112. Hansoh Pharma Company Information

Table 113. Hansoh Pharma Description and Business Overview

Table 114. Hansoh Pharma GLP-1/GIP Dual Receptor Agonist Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 115. Hansoh Pharma GLP-1/GIP Dual Receptor Agonist Product

Table 116. Hansoh Pharma Recent Developments/Updates

Table 117. Key Raw Materials Lists

Table 118. Raw Materials Key Suppliers Lists

Table 119. GLP-1/GIP Dual Receptor Agonist Distributors List

Table 120. GLP-1/GIP Dual Receptor Agonist Customers List

Table 121. GLP-1/GIP Dual Receptor Agonist Market Trends

Table 122. GLP-1/GIP Dual Receptor Agonist Market Drivers

Table 123. GLP-1/GIP Dual Receptor Agonist Market Challenges

Table 124. GLP-1/GIP Dual Receptor Agonist Market Restraints

Table 125. Research Programs/Design for This Report

Table 126. Key Data Information from Secondary Sources

Table 127. Key Data Information from Primary Sources

Table 128. Authors List of This Report

List of Figures

Figure 1. Product Picture of GLP-1/GIP Dual Receptor Agonist

Figure 2. Global GLP-1/GIP Dual Receptor Agonist Market Value by Type (US$ Million), 2021–2032

Figure 3. Global GLP-1/GIP Dual Receptor Agonist Market Share by Type: 2025 & 2032

Figure 4. Balanced Product Picture

Figure 5. Biased Product Picture

Figure 6. Others Product Picture

Figure 7. Global GLP-1/GIP Dual Receptor Agonist Market Value by Receptor Agonist Properties (US$ Million), 2021–2032

Figure 8. Global GLP-1/GIP Dual Receptor Agonist Market Share by Receptor Agonist Properties: 2025 vs 2032

Figure 9. Balanced Product Picture

Figure 10. Biased Product Picture

Figure 11. Others Product Picture

Figure 12. Global GLP-1/GIP Dual Receptor Agonist Market Value by Medicinal Efficacy (US$ Million), 2021–2032

Figure 13. Global GLP-1/GIP Dual Receptor Agonist Market Share by Medicinal Efficacy: 2025 vs 2032

Figure 14. Long-acting Product Picture

Figure 15. Short-acting Product Picture

Figure 16. Global GLP-1/GIP Dual Receptor Agonist Market Value by Application (US$ Million), 2021–2032

Figure 17. Global GLP-1/GIP Dual Receptor Agonist Market Share by Application: 2025 & 2032

Figure 18. Diabetes

Figure 19. Obesity

Figure 20. Others

Figure 21. Global GLP-1/GIP Dual Receptor Agonist Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 22. Global GLP-1/GIP Dual Receptor Agonist Market Size (US$ Million), 2021–2032

Figure 23. Global GLP-1/GIP Dual Receptor Agonist Sales (K Units), 2021–2032

Figure 24. Global GLP-1/GIP Dual Receptor Agonist Average Price (US$/Unit), 2021–2032

Figure 25. GLP-1/GIP Dual Receptor Agonist Report Years Considered

Figure 26. GLP-1/GIP Dual Receptor Agonist Sales Share by Manufacturers in 2025

Figure 27. Global GLP-1/GIP Dual Receptor Agonist Revenue Share by Manufacturers in 2025

Figure 28. Top 5 and Top 10 Global GLP-1/GIP Dual Receptor Agonist Players: Market Share by Revenue in GLP-1/GIP Dual Receptor Agonist in 2025

Figure 29. GLP-1/GIP Dual Receptor Agonist Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 30. Global GLP-1/GIP Dual Receptor Agonist Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 31. North America GLP-1/GIP Dual Receptor Agonist Sales Market Share by Country (2021–2032)

Figure 32. North America GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Country (2021–2032)

Figure 33. United States GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 34. Canada GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Europe GLP-1/GIP Dual Receptor Agonist Sales Market Share by Country (2021–2032)

Figure 36. Europe GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Country (2021–2032)

Figure 37. Germany GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. France GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. U.K. GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Italy GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Russia GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Asia Pacific GLP-1/GIP Dual Receptor Agonist Sales Market Share by Region (2021–2032)

Figure 43. Asia Pacific GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Region (2021–2032)

Figure 44. China GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 45. Japan GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. South Korea GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. India GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Australia GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 49. China Taiwan GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 50. Southeast Asia GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Latin America GLP-1/GIP Dual Receptor Agonist Sales Market Share by Country (2021–2032)

Figure 52. Latin America GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Country (2021–2032)

Figure 53. Mexico GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 54. Brazil GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 55. Argentina GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 56. Colombia GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 57. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Sales Market Share by Country (2021–2032)

Figure 58. Middle East and Africa GLP-1/GIP Dual Receptor Agonist Revenue Market Share by Country (2021–2032)

Figure 59. Turkey GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 60. Saudi Arabia GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 61. UAE GLP-1/GIP Dual Receptor Agonist Revenue Growth Rate (US$ Million), 2021–2032

Figure 62. Global Sales Market Share of GLP-1/GIP Dual Receptor Agonist by Type (2021–2032)

Figure 63. Global Revenue Market Share of GLP-1/GIP Dual Receptor Agonist by Type (2021–2032)

Figure 64. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Type (2021–2032)

Figure 65. Global Sales Market Share of GLP-1/GIP Dual Receptor Agonist by Application (2021–2032)

Figure 66. Global Revenue Market Share of GLP-1/GIP Dual Receptor Agonist by Application (2021–2032)

Figure 67. Global GLP-1/GIP Dual Receptor Agonist Price (US$/Unit) by Application (2021–2032)

Figure 68. GLP-1/GIP Dual Receptor Agonist Value Chain

Figure 69. Channels of Distribution (Direct Vs Distribution)

Figure 70. Bottom-up and Top-down Approaches for This Report

Figure 71. Data Triangulation

Figure 72. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions